A Phase I/II Study of Fixed-Dose Rate Gemcitabine and Bevacizumab for Postoperative Adjuvant Treatment of Patients With Resected Pancreatic Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab; Gemcitabine; Oxaliplatin
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Sep 2012 Biomarkers information updated
- 08 Oct 2008 Planned end date (1 Oct 2007) added as reported by ClinicalTrials.gov.
- 15 May 2008 Status changed from recruiting to in progress, reported by ClinicalTrials.gov